News - Pharmaceuticals
Amgen’s IGF-1R inhibitor marks first therapy PBS listed for thyroid eye disease

Marking the first funded treatment for Thyroid Eye Disease (TED) in Australia, Amgen’s IGF-1R inhibitor Tepezza (teprotumumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) for patients with active moderate-to-severe disease.
TED is a rare and progressive autoimmune condition that can be debilitating and, in severe cases, threaten vision. An estimated 23,000 Australians are living with TED, with approximately 430 new cases of moderate-to-severe disease developing each year.
“Early recognition and referral to treating specialists are important for confirming a diagnosis of TED and assessing the extent of inflammation and severity, which can inform individualised management plans,” said A/Professor Jwu Jin Khong, Ophthalmologist at The Royal Victorian Eye and Ear Hospital in Melbourne.
The unmet clinical need was reflected in the health technology assessment (HTA) process, which attracted submissions from healthcare professionals, consumers, and the Orbital Plastics and Lacrimal (OPAL) and Ocular Rheumatology (EORC) units at the Royal Victorian Eye and Ear Hospital (RVEEH). Their feedback highlighted the considerable burden of active disease, alongside the limited efficacy and safety concerns associated with existing therapies.
The PBS listing, however, follows a protracted process. The Pharmaceutical Benefits Advisory Committee (PBAC) initially recommended teprotumumab at its May 2025 meeting, but the proposal could not progress after the previously proposed price was no longer considered feasible by the sponsor, likely due to global MFN pricing pressures.
The committee subsequently raised concerns about the uncertainty surrounding the revised average number of vials required per treatment course. It determined that a price reduction would be necessary to achieve a cost-effective listing, alongside amendments to the risk-sharing arrangement (RSA) to address uncertainty around estimated vial usage per patient.
The listing also comes as the treatment continues to evolve beyond its established intravenous (IV) formulation. Acquired by Amgen through its $27.8 billion takeover of Horizon Therapeutics in 2023, Tepezza could potentially offer patients a less burdensome administration option, following encouraging clinical results for a subcutaneous formulation.
A recent phase 3 trial has demonstrated that subcutaneous administration via an on-body injector (OBI) can provide comparable performance to the established IV route of administration. The development could offer an alternative to the current treatment regimen, which involves eight infusions administered three weeks apart, with each session lasting between 60 and 90 minutes.
Meanwhile, the TED treatment landscape could become competitive, with Roche eyeing the market with Enspryng (satralizumab), its first-in-class interleukin-6 receptor (IL-6R) inhibitor. The self-injectable therapy has previously received Therapeutic Goods Administration (TGA) approval for use in adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease affecting the optic nerve and spinal cord.
For Australian patients, however, the immediate significance lies in the reimbursement of Tepezza.
“This is an important moment to raise awareness of Thyroid Eye Disease in Australia and the significant impact it can have on a person’s quality of life,” said Seth D. Ginsberg, Co-founder and President of Global Healthy Living Foundation Australia.
Amgen’s Associate Vice President & General Manager for Australia and New Zealand, Keith Jones, said “Amgen is proud to collaborate with the Australian Government and healthcare community to ensure eligible Australians with TED can now access this treatment option through the PBS.”
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More